7+3 Induction (cytarabine + daunorubicin/idarubicin) ± midostaurin
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-CYTARABINE DRUG-DAUNORUBICIN DRUG-MIDOSTAURIN |
|---|
| ID | REG-AML-7-3 |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ELN-AML-2022 SRC-ESMO-AML-2020 SRC-NCCN-AML-2025 SRC-RATIFY-STONE-2017 |
Notes
Standard 1L for fit-for-intensive AML. Add midostaurin if FLT3-ITD/TKD+ (RATIFY: improved 4-y OS 51% vs 44%). Day-14 BM check at end of induction; if blasts persist → re-induction. Consolidation HiDAC 3 g/m² q12h d1, 3, 5 for 3-4 cycles in young fit favorable / intermediate-risk; alloHCT for adverse-risk in CR1. STUB — requires clinical co-lead signoff before publication.
Used By
Algorithms
ALGO-AML-1L- ALGO-AML-1L
Indication
IND-AML-1L-7-3- IND-AML-1L-7-3IND-AML-PEDIATRIC-AAML1031- IND-AML-PEDIATRIC-AAML1031